Head-to-head evidence
Binimetinib vs Trametinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MEK1/2 · full Non-Small Cell Lung Cancer pipeline
Binimetinib
Marketed by Pfizer
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT05355701 (registry estimate)
Trametinib
Marketed by Novartis and partners
NCT01362296 · Phase 2 · completed
This was a randomized, active-controlled trial against a standard chemotherapy comparator, but it was conducted without blinding, and the primary progression-free-survival endpoint was not statistically different between arms (hazard ratio 1.14, 95% CI 0.75 to 1.75, p=0.5197).
Next expected readout: October 2026 · NCT03333343 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Binimetinib's landscape · Trametinib's landscape